Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

29 Mar 2022

Cybin Announces Successful Completion of CYB003 Preclinical Studies

Today we got some follow-up news on Cybin'sB-003 program, with positive pre-clinical results that will hopefully pave the way for their upcoming human trials....

By Jason Najum

Don’t Miss

28 Mar 2022

News You Might Have Missed: March 28th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed....

By Jason Najum

Finance

28 Mar 2022

MindMed Reports 2021 Financial and Business Results

It’s always big news when MindMed is in the headlines....

By Jason Najum

Industry

25 Mar 2022

A Closer Look at Clearmind Medicine

With dozens of companies racing to drive classic psychedelics through clinical trials, or spending years and untold millions developing next-generation versions of these well-known molecules, Clearmind could have its own...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

23 Mar 2022

Heading to Phase 3? PharmaTher Announces Positive Results for Ketamine Trial

If a Phase 3 study is actually in their near future, then PharmaTher would further solidify itself as a serious top tier firm and official king of Ketamine....

By Jason Najum

Don’t Miss

21 Mar 2022

News You Might Have Missed: March 21st, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed...

By Jason Najum

Industry

17 Mar 2022

Awakn Life Sciences Announces New Clinic: A Closer Look

With two advanced Phase 2 studies underway (using both ketamine and MDMA for alcohol addiction) Awakn has quietly put itself in the top tier of companies in terms of clinical...

By Jason Najum

Breaking News, Industry

14 Mar 2022

News You Might Have Missed: March 14th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed....

By Jason Najum

Law & Politics

11 Mar 2022

Psychedelic Decriminalization Update

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.